
Consumer Insights
Uncover trends and behaviors shaping consumer choices today
Procurement Insights
Optimize your sourcing strategy with key market data
Industry Stats
Stay ahead with the latest trends and market analysis.
The head and neck cancer market was valued at USD 3.76 Billion in 2024, driven by the rising cases of head and neck cancer across 8 major markets. The market is anticipated to grow at a CAGR of 7.40% during the forecast period of 2025-2034, with the values likely to reach USD 7.68 Billion by 2034.
Base Year
Historical Year
Forecast Year
The National Cancer Institute estimates that in the United States, approximately 71,100 people will be diagnosed with oral cavity, pharynx, or larynx cancer by the end of 2024. Hence, the United States is expected to lead the market share in the forecast period, driven by the region's rising prevalence of the condition.
One of the major market trends includes a rising emphasis on personalized medicine and a surge in drug approvals to manage the disease effectively.
The market growth is driven by rising collaborations to offer support to head and neck cancer patients and families.
Value in USD Billion
2025-2034
Head and Neck Cancer Market Outlook
*this image is indicative*
Head and neck cancer (HNC) starts in squamous cells that cover mucosal surfaces of the head and neck, such as the mouth, throat, larynx, sinuses, and nasal cavity. Primary categories include cancers of the mouth, throat (nose, mouth, and lower throat), voice box, nasal passages and sinuses, and saliva-producing glands. They affect regions such as lips, gums, throat, voice box, nose, sinuses, and salivary glands. The process of identifying head and neck cancers includes physical examinations, imaging tests, and taking tissue samples for analysis.
Factors that increase risk include using tobacco, drinking alcohol, and being infected with human papillomavirus (HPV). Signs may consist of a continual throat ache, trouble swallowing, loss of voice, and inexplicable bumps. Timely identification is important for improved results, as treatment choices depend on the location and stage of the cancer. Typically, treatment for head and neck cancer includes surgery, radiation, chemotherapy, targeted therapy, and immunotherapy. The choice of treatment depends on the location of the tumor, its stage, the patient's health, and the characteristics of the tumor. Surgery eliminates tumors, then radiation is used to destroy any remaining cancer cells. Chemotherapy and radiation may be combined in more advanced cases. New possibilities for treating advanced or recurrent cases include targeted therapy and immunotherapy.
Increasing Alcohol Consumption Spurs Market Growth
The rising consumption of alcohol plays a significant role in advancing the disease prevalence. The National Survey on Drug Use and Health 2023 found that 224.3 million people aged 12 and older in the United States reported drinking alcohol at some point in their lifetime. This included 111.1 million males and 113.2 million females aged 12 and older. Among youth aged 12 to 17, 5.6 million reported drinking alcohol, with 2.5 million boys and 3.1 million girls in this age group. 218.7 million adults aged 18 and older reported alcohol use, with 108.6 million men and 110.1 million women in this age group. The combination of alcohol and smoking greatly increases the risk of oral, pharyngeal, laryngeal, and esophageal cancers. Even though there have been attempts to educate people about the connection between alcohol and cancer and encourage moderation in drinking, there is still a persistent issue of excessive alcohol consumption leading to an increase in new cancer diagnoses.
Rising Prevalence of Head and Neck Cancer
According to NHS, around 12,400 new cases of head and neck cancer are diagnosed in the United Kingdom annually. The National Cancer Institute estimates that in the United States, approximately 71,100 people will be diagnosed with oral cavity, pharynx, or larynx cancer by the end of 2024, with about 16,110 expected to die from these diseases. The disease prevalence is also expanding because of lifestyle choices such as smoking, and drinking.
The market is witnessing several trends and developments to improve the current scenario. Some of the notable trends are as follows:
The report offers a detailed analysis of the market based on the following segments:
Market Breakup by Treatment Type:
Market Breakup by Route of Administration:
Market Breakup by End User:
Market Breakup by Region:
Market Segmentation Based on Treatment Type to Witness Growth
Based on the treatment type, the market is divided into chemotherapy, immunotherapy, targeted drug therapy, and others. Chemotherapy is expected to dominate the market for the treatment of head and neck cancer, particularly in cases where surgery is not possible, especially in advanced stages. It is frequently combined with radiation therapy or other systemic treatments and utilized in low- and middle-income countries where newer treatments may not be accessible. Chemotherapy has proved to be successful in reducing tumor size and managing disease advancement.
Based on region, the market report covers the United States, EU-4 (Germany, France, Italy, Spain), United Kingdom, Japan, and India. The United States is expected to dominate the market because of higher disease incidence, robust healthcare system, and ongoing research efforts. A rise in cancers among younger adults is creating a need for innovative treatments such as immunotherapy. The market is being supported by advanced diagnostic techniques and government initiatives, prompting pharmaceutical companies to invest significantly in research.
EU-4 and the United Kingdom are also poised to have a significant market share supported by their healthcare systems are robust, with high demand driven by factors such as HPV and lifestyle, as well as strong screening programs. The EMA is backing the growing use of immunotherapy and targeted therapies. Head & Neck Cancer Specialists and Survivors in the United Kingdom established HANCUK, a charity that aims to assist in decision-making, raise awareness for symptoms and treatment of head and neck cancer, and address treatment inequalities.
The key features of the market report include patent analysis, clinical trials analysis, grants analysis, funding, and investment analysis as well as strategic initiatives by the leading players. The major companies in the market are as follows:
Bristol-Myers Squibb focuses on cancer, immunology, cardiovascular, and fibrotic therapies. They launched a Back-to-Work Guide for Head and Neck Cancer Patients in July 2021, providing legal rights information, solutions for challenges post-treatment, and advice on returning to work. The guide is popular among patients, nurses, oncologists, and carers in the United Kingdom.
Eli Lilly, an American pharmaceutical company, offers ERBITUX (cetuximab) in combination with platinum-based chemotherapy for first-line treatment of squamous cell carcinoma of the head and neck. Based on the EXTREME trial data, this regimen shows extended overall survival in patients with recurrent locoregional or metastatic squamous cell carcinoma of the head and neck.
Roche is a biotechnology company providing innovative solutions and drugs for cancer, autoimmune diseases, and other health conditions. They also offer in vitro diagnostics and research novel methods for disease prevention and treatment. A clinical trial is being conducted to compare atezolizumab with placebo for head and neck cancer patients at high risk of recurrence or worsening after initial therapy. The study aims to evaluate the efficacy and safety of atezolizumab as adjuvant therapy.
Merck is a biopharmaceutical company focused on prescription medicines, vaccines, and animal health products. In 2023, Merck and Eisai updated for KEYTRUDA plus LENVIMA in metastatic non-small cell lung cancer. The combination is approved for advanced renal cell carcinoma and certain endometrial cancers. Studies are ongoing for various tumor types, including endometrial carcinoma, hepatocellular carcinoma, RCC, head and neck cancer, gastric cancer, and esophageal cancer.
*Please note that this is only a partial list; the complete list of key players is available in the full report. Additionally, the list of key players can be customized to better suit your needs.*
Other players in the market are AstraZeneca plc, Cumberland Pharmaceuticals Inc., GSK plc, Sanofi, and Takeda Pharmaceutical Company Limited.
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!
Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.
REPORT FEATURES | DETAILS |
Base Year | 2024 |
Historical Period | 2018-2024 |
Forecast Period | 2025-2034 |
Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
Breakup by Treatment Type |
|
Breakup by Route of Administration |
|
Breakup by End User |
|
Breakup by Region |
|
Market Dynamics |
|
Supplier Landscape |
|
Companies Covered |
|
Datasheet
One User
USD 3,299
USD 2,969
tax inclusive*
Single User License
One User
USD 5,499
USD 4,969
tax inclusive*
Five User License
Five User
USD 6,999
USD 5,949
tax inclusive*
Corporate License
Unlimited Users
USD 8,199
USD 6,969
tax inclusive*
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Small Business Bundle
Growth Bundle
Enterprise Bundle
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Number of Reports: 3
20%
tax inclusive*
Small Business Bundle
Number of Reports: 5
25%
tax inclusive*
Growth Bundle
Number of Reports: 8
30%
tax inclusive*
Enterprise Bundle
Number of Reports: 10
35%
tax inclusive*
How To Order
Our step-by-step guide will help you select, purchase, and access your reports swiftly, ensuring you get the information that drives your decisions, right when you need it.
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
Australia
63 Fiona Drive, Tamworth, NSW
+61-448-061-727
India
C130 Sector 2 Noida, Uttar Pradesh 201301
+91-723-689-1189
Philippines
40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City,1226.
+63-287-899-028, +63-967-048-3306
United Kingdom
6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London
+44-753-713-2163
United States
30 North Gould Street, Sheridan, WY 82801
+1-415-325-5166
Vietnam
193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City
+84-865-399-124
United States (Head Office)
30 North Gould Street, Sheridan, WY 82801
+1-415-325-5166
Australia
63 Fiona Drive, Tamworth, NSW
+61-448-061-727
India
C130 Sector 2 Noida, Uttar Pradesh 201301
+91-723-689-1189
Philippines
40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City, 1226.
+63-287-899-028, +63-967-048-3306
United Kingdom
6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London
+44-753-713-2163
Vietnam
193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City
+84-865-399-124
Share